Low-Dose Naltrexone for Lupus (SLE): Evidence, Dosing, and Clinical Considerations
LDN modulates TLR4 signaling and reduces type-I interferon activity in SLE. Review the clinical evidence, dosing titration, flare monitoring, and drug interactions.
Clinical Immunology
Autoimmune Modulation
Low-Dose Naltrexone for Lupus (SLE): Evidence, Dosing, and Clinical Considerations. Part of the Clinical Immunology library by Dr. med. univ. Julian Douwes
